Demystifying Medicine 2016
Tuesdays: January 5 through May 17
4:00pm - 6:00pm
Building 50 Conference Room
(unless otherwise noted)
Final Examination - Deadline May 25, 2016
January 5 - The Age of Insight: The Quest to Understand the Unconscious in Art, Mind and Brain from Vienna 1900 to the Present
January 12 - Ebola, MERS and Likelihood of More Epidemics & Evolutionary Dynamics and Zoonotic and Cross-Species Transmission of Emerging Viruses
- Anthony Fauci, MD (NIAID) -
Anthony S. Fauci, M.D., is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. Since his appointment as NIAID director in 1984, Dr. Fauci has overseen an extensive research portfolio devoted to preventing, diagnosing, and treating infectious and immune-mediated diseases. Dr. Fauci also is chief of the NIAID Laboratory of Immunoregulation, where he has made numerous important discoveries related to HIV/AIDS and is one of the most-cited scientists in the field. Dr. Fauci serves as one of the key advisors to the White House and Department of Health and Human Services on global AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as Ebola and pandemic influenza. He was one of the principal architects of the President's Emergency Plan for AIDS Relief (PEPFAR), which has already been responsible for saving millions of lives throughout the developing world.
Dr. Fauci is a member of the US National Academy of Sciences and is the recipient of numerous prestigious awards for his scientific and global health accomplishments, including the National Medal of Science, the Mary Woodard Lasker Award for Public Service, and the Presidential Medal of Freedom. He has been awarded 42 honorary doctoral degrees and is the author, coauthor, or editor of more than 1,280 scientific publications, including several major textbooks.
- Vincent Munster, PhD (NIAID) - Dr. Vincent Munster received his Ph.D. in virology from Erasmus University, Rotterdam, the Netherlands, in 2006. During his Ph.D. studies, Dr. Munster studied the ecology, evolution, and pathogenesis of avian influenza viruses. He continued his training at the Erasmus Medical Center from 2006 to 2009, where he worked within the Center for Research on Influenza Pathogenesis and Surveillance (CRIPS) focusing on pathogenicity and human-to-human transmission of influenza A viruses. Dr. Munster joined the Laboratory of Virology as a visiting fellow in 2009 to study the ecology of emerging viruses to include filoviruses and henipaviruses. In 2013, Dr. Munster established the Virus Ecology Unit as an independent tenure-track investigator. The mission of the Virus Ecology Unit is to elucidate the ecology of emerging viruses and drivers of zoonotic and cross-species transmission. The Virus Ecology Unit uses a combined field and experimental research approach and conducts research at the state-of-the-art high- and maximum-containment facilities of the Rocky Mountain Laboratories, as well as at field study sites in Africa (the Republic of the Congo, Mali, Liberia), the Caribbean (Trinidad and Tobago), and the Middle East (Jordan). Dr. Munster was awarded the European Scientific Working Group on Influenza (ESWI) Best Body of Work Award for Young Scientists in 2011 and the MERCK-IAAC young investigator award in 2014. Since starting his own laboratory, Munster has been actively involved in the response to the ongoing MERS-CoV and Ebola virus outbreaks.
January 19 - The Future of Medicine: Personalized, Precision and Other
- Eric Green, MD PhD (NHGRI) - Eric D. Green, M.D., Ph.D. is the Director of the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH), a position he has held since late 2009. NHGRI is the largest organization in the world solely dedicated to genomics research. Previously, he served as the NHGRI Scientific Director (2002-2009), Chief of the NHGRI Genome Technology Branch (1996-2009), and Director of the NIH Intramural Sequencing Center (1997-2009).
Born and raised in St. Louis, Missouri, Dr. Green received his B.S. degree in Bacteriology from the University of Wisconsin-Madison in 1981, and his M.D. and Ph.D. degrees from Washington University in 1987. During residency training in clinical pathology (laboratory medicine), he worked in the laboratory of Dr. Maynard Olson, where he launched his career in genomics research. In 1992, he was appointed Assistant Professor of Pathology and Genetics as well as a Co-Investigator in the Human Genome Center at Washington University. In 1994, he joined the newly established Intramural Research Program of the National Center for Human Genome Research, later renamed the National Human Genome Research Institute.
While directing an independent research program for almost two decades, Dr. Green was at the forefront of efforts to map, sequence, and understand eukaryotic genomes. His work included significant, start-to-finish involvement in the Human Genome Project. These efforts eventually blossomed into a highly productive program in comparative genomics that provided important insights about genome structure, function, and evolution. His laboratory also identified and characterized several human disease genes, including those implicated in certain forms of hereditary deafness, vascular disease, and inherited peripheral neuropathy.
As Director of NHGRI, Dr. Green is responsible for providing overall leadership of the Institute's research portfolio and other initiatives. In 2011, Dr. Green led NHGRI to the completion of a strategic planning process that yielded a new vision for the future of genomics research, entitled Charting a course for genomic medicine from base pairs to bedside (Nature 470:204-213, 2011). Since that time, he has led the Institute in broadening its research mission; this has included designing and launching a number of major programs to accelerate the application of genomics to medical care. With the rapidly expanding scope of genomics, his leadership efforts have also involved significant coordination with multiple components of the NIH, as well as other agencies and organizations.
Beyond NHGRI-specific programs, Dr. Green has also played an instrumental leadership role in the development of a number of high-profile efforts relevant to genomics, including the Smithsonian-NHGRI exhibition Genome: Unlocking Life's Code, the NIH Big Data to Knowledge (BD2K) program, the NIH Genomic Data Sharing Policy, and the U.S. Precision Medicine Initiative. Biosketch
January 26 - Canceled Due to Weather - Rescheduled to May 17
February 2 - Where Do Viruses Come From and How Do They Do What They Do? & From A to E: 2000 Years of Hepatitis Virus History
February 9 - The Intestinal Microbiome and Inflammatory Bowel Disease
- Yasmine Belkaid, PhD (NIAID) - Dr. Yasmine Belkaid obtained her Ph.D. in 1996 from the Pasteur Institute in France in the laboratory of Dr. Genevieve Milon exploring innate immune responses to parasites. Following a postdoctoral fellowship at the National Institute of Allergy and Infectious Diseases (NIAID) under the supervision of Dr. David Sacks she joined the Children's Hospital Research Foundation in Cincinnati as an assistant professor. In 2005, she joined NIAID and was appointed Senior Scientist in 2008. She is currently the chief of the Mucosal Immunology section and co-directs the trans-NIH metaorganism initiative. Her work explores mechanisms that regulate host immune responses to pathogens at barrier sites and revealed key roles for the microbiota and dietary factors in the maintenance of tissue immunity and homeostasis.
- Warren Strober, MD (NIAID) - Biosketch
February 16 - Atopy: The Common and The Rare Allergies in the Genomic Era
February 23 - "Shingles" (Herpes Zoster) Revisited
March 1 - Cell Polarity: Mechanisms and Disease in the Nervous System and Liver
- Juan Bonifacino, PhD (NICHD) - Dr. Juan Bonifacino received his doctoral degree in biochemistry from the University of Buenos Aires, Argentina, in 1981. He then moved to the NIH, where he pursued postdoctoral studies with Dr. Richard D. Klausner. He rose through the ranks, eventually becoming Associate Scientific Director of the Cell Biology and Neurobiology Branch, NICHD, NIH. In 2008, he was appointed NIH Distinguished Investigator. Since the early 1990s, Dr. Bonifacino's group has conducted research on signals and adaptor proteins that mediate protein sorting to endosomes and lysosomes. His group discovered new sorting signals and adaptor proteins, and applied this knowledge to the elucidation of the causes of various human diseases including the Hermansky-Pudlak syndrome type 2 and autosomal dominant polycystic liver disease. Dr. Bonifacino has served in various editorial capacities for journals including Developmental Cell, Molecular Cell, Molecular Biology of the Cell, Journal of Cell Biology, Journal of Biological Chemistry, Traffic, and Frontiers in Neuroscience. He is also an editor of the books Current Protocols in Cell Biology and Short Protocols in Cell Biology. He has served as a member of the Council of the American Society for Cell Biology, and chaired various scientific conferences. He has delivered the Alex Novikoff, Leonardo Satz, George Connell and G. Burroughs Mider lectures, and is an Honorary Professor of Biological Chemistry at the University of Buenos Aires and a Sackler Lecturer at Tel Aviv University, Israel. His lab has trained over 70 postdoctoral fellows and students, most of whom have pursued careers in academic research.
- Irwin Arias, MD (CC/NICHD)
March 8 - Depression: Neuromodulation Meets Super-Resolution Cell Biology
March 15 - Non Alcoholic Fatty Liver Disease and Steato-Hepatitis (NAFLD/ NASH): An "Epidemic" Liver Disease Requiring New Drugs
- Yaron Rotman, MD (NIDDK) - Dr. Rotman is a Tenure-Track Investigator and chief of the Liver and Energy Metabolism Unit at the Liver Diseases Branch of NIDDK. He graduated from the Hadassah Medical School of the Hebrew University in Jerusalem, Israel, where he also had his first exposure to research, studying for a Masters degree in neurophysiology of the auditory cortex . After realizing that despite the fascinating research in the field, neither clinical ENT nor neurology interested him, he completed Internal Medicine residency and Gastroenterology and Hepatology fellowship at Rabin Medical Center in Petach Tikva, Israel. He subsequently came to the Liver Diseases Branch of NIDDK for a hepatology clinical research fellowship and since August 2009, has been on faculty, initially as an Assistant Clinical Investigator and currently as a Clinical Investigator. His research focused for many years on hepatitis C but in the past years shifted, with his main interest currently in studying the pathophysiology of fatty liver disease. Dr. Rotman won several awards and is currently the principal investigator of several clinical trials. In his free time he enjoys raising his children, baking bread and running to compensate for that.
- Rosana Kapellar, MD PhD (Nimbus) - Dr. Rosana Kapeller is Chief Scientific Officer of Nimbus Therapeutics and holds responsibility for advancing the company's programs from discovery to early human proof-of-concept. In addition to spearheading Nimbus' scientific vision, Dr. Kapeller co-led the Series A funding for the company in 2011 and has worked closely with other members of the management team to create multiple strategic business opportunities for the company, including partnerships and collaborations with Schrodinger, Monsanto, Shire and Genentech. Before joining Nimbus, Dr. Kapeller was Vice President of Research and a Co-Founder of Aileron Therapeutics, where she led the development of that company's "Stapled Peptide" technology. Under her leadership, Aileron secured $60 million in venture financing over its first four years. Prior to co-founding Aileron, Dr. Kapeller held positions of increasing responsibility at Millennium Pharmaceuticals, most recently serving as Director, Molecular and Cellular Biology. Dr. Kapeller earned her M.D. from Rio de Janeiro State University in Brazil, and her Ph.D. from Tufts University Medical School. She conducted her post-doctoral research work at the Dana-Farber Cancer Institute where she was named a David Abraham Fellow in Pediatric Oncology. In 2012, Dr. Kapeller was named one of the Top 20 Women to Watch by Mass High Tech. She currently serves as a scientific advisor to Atlas Venture.
March 22 - Progress in Understanding Congenital Heart Disease (The #1 Killer in Birth Defects): Mechanisms and New Technologies
March 29 - The Oral Microbiome Meets Cell Biology and Periodontal Disease
April 5 - Multiple Sclerosis: Mechanisms and Imaging the Process
- Daniel Reich, MD PhD (NINDS) - Dr. Daniel Reich directs the Translational Neuroradiology Unit at the National Institute of Neurological Disorders and Stroke. He leads clinical studies focusing on multiple sclerosis at the NIH Clinical Center. In his practice as a neuroradiologist, he cares for patients with MS and other neurological diseases.
Dr. Reich earned his MD at Cornell and his PhD in neurophysiology from The Rockefeller University, where he studied how nerve cells encode and process visual information. He holds an undergraduate degree in math and physics from Yale. His training includes a fellowship in diagnostic neuroradiology and residencies in radiology and neurology at Johns Hopkins. He serves on the Advisory Committee of the Americas Committee for Treatment and Research in Multiple Sclerosis, the Scientific Advisory Board of the Race to Erase MS, and the Editorial Board of Multiple Sclerosis Journal. He is the 2015 winner of the American Neurological Association's Derek Denny-Brown Young Neurological Scholar Award in Clinical Science.
Research in Dr. Reich's lab uses advanced MRI techniques to understand multiple sclerosis and other inflammatory diseases of the central nervous system, and on ways of adapting those techniques for use in clinical trials and patient care. The lab is particularly interested in harnessing noninvasive imaging modalities to dissect biological mechanisms of tissue damage, both by performing longitudinal studies on time scales relevant for disease processes and by examining radiological-pathological correlations in autopsy tissue and animal models. These experiments make use of state-of-the-art ultra-high-field MRI scanners, interfacing with many outstanding imaging science groups on campus.
- Irene Cortese, MD (NINDS) - Dr. Irene Cortese is a board-certified neurologist and the Chief of the Neuroimmunology Clinic. She
earned her medical degree from the University of Rome "Tor Vergata" in Italy with a doctoral thesis exploring the specificity
of oligoclonal bands in the CSF of patients with MS. She went on to obtain her neurology residency, while still maintaining her laboratory
interests. While a resident, she was awarded a 3 year grant from the Italian MS Society (AISM) to fund her research.
In 1998 she came to the NIB as a research fellow in Roland Martin's lab, during which time she focused on the cellular immune
response in MS. In order to pursue her interests in clinical and translational research, she obtained US credentialing via a
second residency in neurology and fellowship at Johns Hopkins. She returned to NIH in 2005, first as a clinical fellow and
subsequently as a staff clinician heading the Neuroimmunology Clinic. She currently co-directs the clinical neuroimmunology fellowship
program at NIH, together with Dr. Nath. As director of the Neuroimmunology Clinic, Dr. Cortese oversees the implementation of clinical
studies, including natural history and treatment protocols, in support of and in collaboration with the other investigators in the
Division of Neuroimmunology and Neurovirology Diseases, including Drs. Steven Jacobson, Avindra Nath, and Daniel Reich. A main research
focus of the group as a whole is the development of novel outcomes for use in clinical trials. As a result of these studies, a novel
trial design was developed at NIH which proposes to use a novel trial design taking advantage of a lesion-based outcome to measure
neuroprotection/neurorepair. This has led to the actively recruiting Phase I study of guanabenz as a neuroprotective
agent for MS, for which Dr. Cortese is the Principal Investigator.
April 12 - Global Warming: Effect on Vector Distribution, Disease and Natural Product Research
- Jonathan Sleeman, PhD (USGS)
- David Newman, PhD (NCI) - David Newman retired as Chief of the Natural Products Branch (NPB) at the DTP/NCI in Frederick, MD in
early January 2015 having spent almost 24 years with the branch, the last 10 as Chief. Born in the UK he has an M.Sc. in synthetic
organic chemistry (Liverpool) a D. Phil.
in microbial chemistry (Sussex) and an MSLS in Information Science (Drexel). He came to the USA in1968 (post-doc in Biochemistry
at UGA), then Smith Kline & French (now GSK) as a biological chemist 1970-85 working mainly on antibacterial and antifungal agents
from microbes. In 1985 he left SK&F (closed anti-infective program), worked in marine and microbial discovery programs at various
companies in the USA, and joined the NPB in 1991. Research interests are in natural product structures as leads to drug candidates
and their subsequent development to drugs. Two leads that he worked on over the years have become approved drugs, one antibacterial
(ardicin) and one antitumor (halaven), with a significant number of other compounds reaching clinical trials in man in cancer.
He is the author or coauthor of over 175 papers, reviews and book chapters related to natural products and close chemical relatives,
and holds 21 patents (UK, WIPO and USA) mainly on microbial products. He is a Chartered Chemist (CChem, FRCS) and a Chartered
Biologist (CBiol, FRSB) in the UK and EU, and now has a small consulting business covering natural products and their utility as
drug leads / drugs.
April 19 - Trauma in the Modern Age: Injury and Stem Cells
April 26 - Hepatocellular Cancer: Problems and Progress in an Epidemic Disease
May 3 - Cholesterol: Too Much and Too Little are Bad for Your Health
- Forbes Porter, MD, PhD (NICHD) - Biosketch
- Robert Shamburek, MD (NHLBI) - Dr. Shamburek is a staff clinician in charge of the inpatient ward and outpatient Lipid Clinic in the Cardiovascular and Pulmonary Branch at the NHLBI, at NIH. His overall interests are in lipoprotein metabolism. He trained in gastroenterology and studied in vivo cholesterol kinetics in human and animal models. Over the last two decades he have been involved in studies at the NIH on in vivo lipoprotein and apolipoprotein kinetics in human and animal models initially in Dr. B. Brewer's laboratory. The research focus of his research program has been to study subjects with rare genetic lipid disorders. The main goal of the program is to characterize rare lipid phenotypes and ultimately discover the gene responsible for the defect. The discovery of new apolipoproteins, lipoprotein receptors, lipid transfer proteins and enzymes has allowed the elucidation of the lipid metabolic defects and pathways in patients with unusual rare dyslipoproteinemia.
May 10 - Robotic Planetary Exploration and Thoughts about Human Spaceflight
May 17 - How Long Can and Should We Live? & What Centenurians Teach Us about Aging
- Luigi Ferrucci, MD (NIA) - Biosketch
- Nir Barzilai, MD (Albert Einstein College of Medicine) - Dr. Barzilai is a chaired Professor of Medicine and Genetics and the Director of the Institute for Aging Research at the Albert Einstein College of Medicine, which is currently the biggest Center in the world to study the Biology of Aging. This Institute is the home of the Nathan Shock Center of Excellence in the Biology of Aging and the Glenn center for the Biology of Human Aging. His interests focus on several basic mechanisms in the biology and genetics of aging. He is the recipient of an NIH a Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of Ashkenazi Jewish centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He is a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research. Dr. Barzilai is in the board of the American Federation for Aging Research, is its co-scientific director, and has served on several NIA study section. He is also a founder of CohBar Inc., a biotech that develops mitochondrial derived peptides as therapy for aging and its diseases. He is co-PI on the R24 Geroscience (Apollo) grant that is an effort to move the field of aging to translation. He is leading the TAME (Targeting/Taming Aging with MEtformin) multi central study to prove that concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions. His work has been profiled by major outlets, including the New York Times, the BBC and PBS' NOVA science now, TEDx talk Science and is the leading feature on the Ron Howard/Jonathan Silberberg/National Geographic film about the Age of Aging.
This web page was last modified on 27 May 2016. For questions about the course, please contact email@example.com.